Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

>.  

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2014)... , July 18, 2014  Neogen Corporation (Nasdaq: ... Snyder , Neogen,s chief operating officer and president, has ... will work as a consultant going forward on special ... Snyder has been in this position since September 2013. ... by James Herbert , who has been Neogen,s ...
(Date:7/18/2014)... That is, most of the atoms in our ... in the outer parts of atoms equals the number ... one or more electrons are plucked away from the ... pull from the nucleus. This enhanced pull, causing ... electrons are less vulnerable to the distractions of their ...
(Date:7/18/2014)... , July 18, 2014  Neurotrope, Inc. (OTCQB: NTRP) ... of Directors appointed Co-Chairmen Charles S. Ramat ... on an interim basis, effective immediately. Messrs. Ramat and ... no longer Chief Executive Officer of Neurotrope Bioscience, Inc., ... and whose employment agreement with Neurotrope Bioscience Inc. terminated ...
(Date:7/18/2014)... Emerging Nuclear Power Countries - Market Forecast, ... , The latest report from GlobalData, Emerging Nuclear Power ... to 2030 covers the emerging nuclear market and the ... on key market players and their global market share. ... across the world has also been estimated. , To ...
Breaking Biology Technology:Highly charged ions 2Highly charged ions 3Highly charged ions 4Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 2Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 3Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 4Emerging Nuclear Power Countries - Market Forecast, Key Companies and Development Analysis, Size, Share, Growth, Trend to 2030 2Emerging Nuclear Power Countries - Market Forecast, Key Companies and Development Analysis, Size, Share, Growth, Trend to 2030 3
... electrical hair that lets them link up in ... Southern California biophysicist and his collaborators. The ... and share energy in part through electrically conducting ... the first measurement of electron transport along biological ...
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) announced ... product candidate, fidaxomicin, will be presented ... Disease Society of America (IDSA) to be held at ... on October 21-24, 2010. (Logo: ...
... N.J. Physicists at Rutgers University have discovered new ... and inexpensive plastic solar cells for pollution-free electricity production. ... in an upcoming issue of the journal Nature ... of light can travel on the order of a ...
Cached Biology Technology:Microbial hair: It's electric 2Microbial hair: It's electric 3Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting 2Rutgers discovery paves way for development of efficient, inexpensive plastic solar cells 2
(Date:7/21/2014)... has issued a high health risk warning for Yellowknife ... region due to forest fires. Currently 160 wildfires ... plans for evacuation since these fires are endangering people ... area recently comes with mixed results. The rains ... to start others. , This year the Northern Territories ...
(Date:7/21/2014)... School of Medicine-led study suggests that parents of obese ... consequences of childhood weight gain or the importance of ... healthy weight. , The study is published online in ... Dietetics . , "Parents have a hard time changing ... author Kyung Rhee, MD, and an assistant adjunct professor ...
(Date:7/21/2014)... Aqua satellites detected 154 hotspots in areas across Riau ... fires had increased again following a decline in rainfall. ... was far higher than what had been reported one ... The hotspots were scattered in six regencies and municipalities, ... Smoke and the related haze it creates could potentially ...
Breaking Biology News(10 mins):Parents rank their obese children as 'very healthy' 2
... A newly identified defect in a DNA repair system might ... a key chemotherapy drug, possibly putting them at greater risk ... by St. Jude Children,s Research Hospital scientists. The ... acute lymphoblastic leukemia (ALL) patients who are at higher risk ...
... compound tested by UT Southwestern Medical Center investigators destroys several ... 30 million people in the worldwide pandemic of 1918. ... of a human antiviral protein - could potentially be developed ... that tends to mutate into strains resistant to anti-influenza drugs. ...
... [Brown University] Take your time. Hold your horses. ... arguably equal choices, they need time to deliberate. In ... for Parkinson,s disease, that process sometimes doesn,t kick in, ... happens has led scientists to a detailed explanation of ...
Cached Biology News:Newly identified DNA repair defect linked to increased risk of leukemia relapse 2Newly identified DNA repair defect linked to increased risk of leukemia relapse 3Compound kills highly contagious flu strain by activating antiviral protein 2DBS studies show how brain buys time for tough choices 2DBS studies show how brain buys time for tough choices 3
UGT1A7 (E-15)...
... peptide corresponding to the third cytoplasmic loop ... conjugated to KLH. The immunizing peptide has ... gene. Physical form: Solution in phosphate ... azide. Titertest method: IHC (p). ...
... Human Pathogenic Viruses The National ... preserves well characterised, authenticated human ... facility, and NCPV is able ... nucleic acids derived from them, ...
... easy to use Ascent Software ... members of the Ascent microplate ... clear and easy-to-follow approach with ... and highly sophisticated data handling, ...
Biology Products: